Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program

-Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early le...

June 29, 2023 | Thursday | News
FDA Approves Pfizer's NGENLA™, Weekly Treatment for Pediatric Growth Hormone Deficiency

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon...

June 29, 2023 | Thursday | News
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve

The strategic stockpile has been established to enable rapid deployment to EU member states and other countries participating in the EU Civil Protection Me...

June 26, 2023 | Monday | News
QIAGEN's QuantiFERON-TB Gold Plus Shows Unique Clinical Benefits in Tuberculosis Screenings

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...

June 16, 2023 | Friday | News
ACROBiosystems Aneuro Teams Up with Diagnostic Biochips for Neuroscience Drug Discovery

Electrophysiology is a critical part of neuroscience research, especially when attempting to elucidate the neural network. Monitoring the brain's field pot...

June 14, 2023 | Wednesday | News
Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

This study, conducted by experts from Aquarius Population Health Limited in London and the University of Manchester, presents valuable insights into the co...

June 14, 2023 | Wednesday | Analysis
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy

Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life fo...

June 13, 2023 | Tuesday | News
FDA Committee Unanimously Recommends Nirsevimab as First RSV Immunization for Infants

Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approved Across all clinical ...

June 09, 2023 | Friday | News
Lecanemab's Alzheimer's Treatment Application Filed in South Korea

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab...

June 08, 2023 | Thursday | News
Jackson Laboratory Engages in Rare Disease Therapy Research

Researchers led by Cathleen Lutz, Ph.D., are using an exciting new method, preclinical genomic editing, to develop safe, effective therapies for rare disea...

June 07, 2023 | Wednesday | News
Hansa Begins Global Phase 3 Trial for Imlifidase in Anti-GBM Disease

Søren Tulstrup, President and CEO, Hansa Biopharma said, "This is an exciting next step in the development of imlifidase and for patients with anti-...

May 30, 2023 | Tuesday | News
Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for EU Marketing Authorization in COVID Prevention

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant,  announced that Nuvaxovid&tra...

May 29, 2023 | Monday | News
KEYTRUDA® + LENVIMA® Show Long-Term Survival Benefit in Advanced Renal Cell Carcinoma

After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581...

May 26, 2023 | Friday | News
FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria

According to the World Health Organization, Acinetobacter species top the list of critical bacterial pathogens that pose the greatest threat to human ...

May 24, 2023 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close